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Abstract. The brain tripeptide thyrotropin-releasing hor- 
mone (TRH) has been demonstrated to facilitate cholinergic 
neurotransmission. To test its interaction with the choliner- 
gic system in humans, high-dose TRH (0.5 mg/kg) or pla- 
cebo was administered intravenously (IV) to normal con- 
trols pretreated with scopolamine (0.5-0.75 mg IV), a cen- 
trally active muscarinic antagonist, which has been used 
to model aspects of the memory impairment of normal ag- 
ing and of dementia. Compared to placebo, TRH markedly 
attenuated scopolamine-induced impairment of some mea- 
sures of memory, most notably on a selective reminding 
task. This cognitive study is the first in humans to suggest 
a neuromodulatory effect of a peptide on the cholinergic 
system, and suggests a facilitatory role for TRH in human 
memory processes. 
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Thyrotropin-releasing hormone (TRH), a tripeptide origi- 
nally described for its effects on the pituitary-thyroid axis, 
has been found to be distributed throughout the brain (Met- 
calf 1982). The highest concentrations of  TRH receptors 
in human brain are in the limbic system, specifically in 
the amygdala, hippocampus, and temporal cortex (Man- 
aker et al. 1986). In animal studies, TRH has been shown 
to interact with several neurotransmitters. Of these interac- 
tions, the positive neuromodulatory effects of TRH on the 
cholinergic system are the best delineated (Breese et al. 
1975; Yarbrough 1979; Kalivas and Horita 1980; Horita 
et al. 1986). For this reason, TRH and its synthetic analogs 
have been proposed to have potential therapeutic value in 
diseases with deficits in the cholinergic system, such as Alz- 
heimer's disease (Yarbrough 1979; Metcalf 1982). 
Scopolamine, a centrally active anticholinergic drug that 
impairs memory, has been shown in previous pharmaco- 
logic studies of normal controls to mimic the cognitive im- 
pairment of aging or even dementia (Drachman 1977; 
Caine et al. 1981 ; Sunderland et al. 1986). In patients with 
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Alzheimer's disease, loss of cholinergic markers has in fact 
been correlated with dementia severity (Perry et al. 1978), 
and patients with Alzheimer's disease have been shown to 
be more sensitive to the amnestic effect of scopolamine than 
age-matched controls (Sunderland et al. 1987). 
In the present study, we tested the effects of intravenous 
(IV) TRH in the human scopolamine model of memory 
impairment. We hypothesized that TRH would reverse the 
memory impairment caused by scopolamine through its fa- 
cilitatory effect on the cholinergic system. To obtain central 
cognitive effects, we administered a very high dose of TRH 
because it crosses the blood-brain barrier poorly (Metcalf 
1982) and is quickly metabolized, having a plasma half-life 
of only 4-5 rain (Bassiri and Utiger 1973). 
Methods 
Subjects 
Twelve normal paid volunteers (8 females, 4 males; mean 
age 26.9_7.9years;  mean years of education 14.4+1.2) 
participated in the study after signing informed consent. 
Body weight of the subjects ranged from 57 to 96 kg 
(mean=76.5-t-12.8 kg). Volunteers were screened to ex- 
clude those with medical or psychiatric illness; all subjects 
were drug-free for at least 3 weeks prior to the study. 
Cognitive tests 
A baseline cognitive battery, which was administered to 
all subjects, included the Weschler Memory Scale and sever- 
al tests of attention, memory, and learning as follows. 
Selective reminding task. A list of 12 unrelated words was 
read and subjects were asked to recall the list; missed words 
were repeated by the examiner and subjects were again 
asked to recall them (Buschke 1973). This process was re- 
peated for a total of eight trials. Two scores were obtained 
from this task, one for free recall and the other for con- 
sistency of recall, which is the mean number of words re- 
called prior to reminding by the examiner for each trial. 
Scores from this task have previously been used to measure 
episodic learning and memory and effort-demanding mem- 
ory processes (Weingartner et al. 1983). Scores were re- 
corded for the full task (all eight trials), and were also bro- 
ken down into the early (14)  and late (5-8) trials for both 
free recall and recall consistency. 
Vigilance task. Subjects were read a list of 12 categorically 
related words, 6 of which were repeated; subjects were in- 
structed to signal the examiner upon hearing a word for 
the second time. The score was the number of correctly 
identified twice-presented words; this was used as a measure 
of vigilance-attention. After a distractor task (counting 
backward), subjects were asked to recall as many items 
from the list as possible. This free recall score was one 
of the measures used to evaluate recent or episodic memory. 
Next, subjects were read a list of 24 categorically related 
words, 12 of which were from the previous list and 12 of 
which were new. Subjects were asked to indicate whether 
a word was old or new. The number of correctly identified 
words, scored separately for old and new words, was used 
as a measure of recognition memory. Of the correctly identi- 
fied old words, subjects were asked to judge the original 
frequency of presentation (once or twice); the difference 
between the mean reported frequency of once- and twice- 
presented words was used as a measure of automatic ep- 
isodic memory processes (Weingartner et al. 1984). 
Category retrieval. Subjects were given two stimuli words 
and asked to generate as many associated words as possible 
within a 90-s period. Subjects were then given two letters 
and asked to generate words beginning with each letter, 
also within a 90-s period. This test was used to assess knowl- 
edge or semantic memory (Weingartner et al. 1984). 
Digit span. Random sequences of digits were read to sub- 
jects who then immediately attempted to recall the digits. 
Forward digit span was used as a test of attention. The 
backward digit span, which is considered a test of episodic 
memory and attention, was also used. 
Object recall. In a test commonly used to assess episodic 
memory, the names of three common objects were read 
to subjects, who then attempted to recall them after 5 min. 
Experimental design 
Following the baseline cognitive battery, subjects partici- 
pated in two study days, separated by at least 72 h (Ta- 
ble I). On each study day, after an overnight fast, an in- 
dwelling IV catheter was inserted; scopolamine hydrobro- 
mide (0.5 or 0.75 mg) was then given to subjects by IV 
push over I min. The higher dose of scopolamine was given 
to subjects weighing over 82 kg (N= 5). This dose was cho- 
sen because findings from a previous study showed more 
Table 1. Experimental design 
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variability in drug levels after mg/kg dosages than after 
a set dose (Safer and Allen 1971). However, because our 
range of subject body weights was wide, we decided to give 
a higher dose to those with the highest weights to try to 
obtain a more standardized effect from the scopolamine. 
Forty-five minutes after subjects received scopolamine, 
they received either high-dose TRH or placebo by IV push 
over 1 rain. The TRH and placebo were given in a double- 
blind manner and were randomized between the 2 study 
days. The timing of drug administration and of cognitive 
testing was based on prior studies in humans showing that 
the cognitive effects of IV scopolamine peak from 90 to 
150 min after administration (Safer and Allen 197t) and 
that central effects of high-dose TRH occur between 30 
and 90 rain after IV infusion (Mellow et al. 1989). Further- 
more, TRH levels in cerebrospinal fluid have been shown 
to peak 40 min after administering TRH (25 rag) subcuta- 
neously, with levels still markedly elevated 120 rain after 
administration (Mitsumoto et al. 1986). 
TRH was purchased from Peninsula Laboratories (Bel- 
mont, CA) and analyzed for purity using high-performance 
liquid chromatography (HPLC) by the NIH Pharmaceuti- 
cal Development Service. 
The selective reminding, vigilance, and category retrie- 
val tasks were administered once on each study day by 
a tester blind to the drug condition. The digit span and 
object recall tasks were performed along with behavioral 
ratings by the physician investigator at 4 points on each 
study day (Table 1). Behavioral and physical effects of the 
drugs were evaluated with both self-ratings and physician 
ratings. Self-ratings included two visual analog scales (VAS) 
and the NIMH self-rating scale and symptom checklist (van 
Kammen and Murphy 1975). The physician completed the 
modified Brief Psychiatric Rating Scale (BPRS) (Overall 
and Gorham 1962) and the Pfeiffer Short Portable Mental 
Status Questionnaire (SPMSQ) (Pfeiffer 1975). 
Blood pressure and heart rate were recorded every 5 min 
with an automated vital signs monitor (Critikon Inc., 
Tampa, FL); oral temperature was also measured at the 
-15,  0, +45, + 60, + 90, + 120, and + 150 rain time points 
on each study day. 
Statistical analysis 
Cognitive data were analyzed by one-way repeated mea- 
sures analysis of variance (ANOVA), with a priori contrast 
comparisons carried out between drug conditions. Based 
on our hypothesis that attenuation of the scopolamine-in- 
duced memory impairment would occur and on evidence 
from prior studies (Itorita et al. 1986; Yamazaki et al. 1986; 
Mellow et al. 1989), we used one-tailed probabilities. Also, 
because of prior studies describing an analeptic effect of 
TRH (Breese et al. 1975; Horita et al. 1986; Mellow et 
al. 1989), we used one-tailed probabilities in the repeated 
measures ANOVA of the behavioral data to compare sco- 
polamine+placebo with scopolamine+TRH, so that we 
could maximize detection of a significant stimulant effect 
on the day subjects received TRH. Thus, one-tailed proba- 
bilities were used in the analysis of cognitive data to insure 
consistency with the one-tailed analysis used for the behav- 
ioral data. Because prior studies (Breese et al. 1975; Horita 
et al. 1986; Mellow et al. 1989) forced us to consider behav- 
ioral activation or increased alertness secondary to TRH 
as a cause of improved cognitive performance, possible rela- 
86 
t ionships between cognitive measures and measures of  acti- 
vat ion were examined by doing correlat ions between scores 
from the selective reminding task and the "d rows iness"  
and "a l e r tness"  items from the self-rating scales. A subset 
of  analog scale behavioral  measures (items evaluat ing levels 
of  alertness, concentrat ion,  and drowsiness) were compared  
between drug condit ions using the maximum change from 
baseline (max delta) for each item. Paired t-tests (one-tailed) 
were used for this comparison.  
Physiologic da ta  (systolic and diastolic b lood  pressure, 
hear t  rate,  and temperature)  were analyzed using repeated 
measures A N O V A  using seven pre-selected t ime points  for 
each pro tocol  day :  - 1 5 ,  0, +45 ,  +60 ,  +90 ,  +120,  and  
+ 150 min (Table 1). Retrospectively,  we decided to com- 
pare  the peak  recorded b lood pressures and heart  rates for 
each study day  using pa i red  t-tests; one-tailed tests were 
used because of  pr ior  studies repor t ing T R H  to cause a 
pressor  effect peaking from 2 to 5 rain after adminis t ra t ion 
(Borowski et al. 1984). This peak effect would have oc- 
curred at  about  the + 5 0  min time point  in our design 
(5 min after T R H  administrat ion) ,  so the b lood pressure 
and hear t  rate recorded closest to this point  were used to 




On the Weschler  Memory  Scale, the mean score of  all sub- 
jects was 115.8_ 14.8; all scores were within normal  limits. 
See Table  2 for  scores on the other  tests. 
Cognitive tests 
Selective reminding task. Subjects performed poor ly  on this 
task after scopolamine.  Subjects receiving TRH,  as com- 
pared  to placebo,  showed a statistically significant a t tenua-  
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Fig. 1. The graph represents scores from the selective reminding 
task expressed as percentage of baseline scores. Attenuation of 
memory impairment after TRH was most evident on the late trials 
(5-8) of the task for both the free recall and consistency of recall 
scores. This comparison of late versus early trials represents in- 
creased efficiency of learning (Weingartner et al. 1983) (* P < 0.05; 
** P<0.01, ***P<0.001). [] Scopolamine+placebo; • Scopola- 
mine + TRH 
tion of  this scopolamine-induced cognitive impairment .  F o r  
both free recall and recall consistency scores, most  o f  this 
improved performance was caused by higher scores on the 
late trials of  the task (Fig. 1). 
Vigilance task. The vigilance-attention score reflected no 
significant drug effect; it  was essentially unchanged from 
baseline after either s copo lamine+p lacebo  or  scopola-  
mine + T R H .  Free recall as assessed by this task declined 
on the scopolamine + placebo day  as compared  with base- 
line, and did not  improve significantly on the day subjects 
received s c o p o l a m i n e + T R H  as compared  with scopola-  
mine + placebo.  On the list o f  words  used to assess recogni- 
t ion memory,  a decline from baseline was statistically signif- 
icant only for the new words (i.e., these words  were not  
as well recognized as words repeated from a pr ior  list). 
The decline in this measure of  recognit ion memory  was 
at tenuated significantly by TRH.  Results on the automat ic  
Table 2. Comparison of the cognitive effects of scopolamine + placebo versus scopolamine + TRH 
Baseline Scopolamine + placebo Scopolamine + TRH F( I, 11) P 
Selective reminding 
Free recall 9.34__ 1.78 5.89 + 1.93 6.98_ 1,60 3.72 
Recall consistency 0.76 ___ 0.20 0.38 + 0.22 0.57 _ 0.21 10.48 
Vigilance task 
Vigilance-attention 5,08 + 1.38 5.17 ___ 0.83 5,33 _ 0.78 0.65 
Vigilance free recall 9.25 __+ 1.42 5.75 + 2.42 6.42 _ 1.62 0.88 
Recognition of old words 10.92+ 1.31 10.67 ___ 1.23 10.75 + 1.36 0.03 
Recognition of new words 10.17___1.90 8.92__+2.54 10.33±1.37 8.05 
Word frequency 0.47 ± 0.33 0.34 + 0.40 0.42_ 0.32 0.67 
Category" retrieval 
Words 22.75 +_ 7.79 16.67 4- 6.78 16.83 d: 3.93 0.01 
Letters 19.92 + 5.07 14.63 ± 6.14 17.54 _ 6.31 26.47 
Other cognitive measures 
Forward digit span 7.79 + 0.66 7.00 +__ 1.00 7.17 +__ 0.72 1.00 
Backward digit span 6.04 ± 0.58 5.36 + 0.67 5.83 _ 0.72 3.38 













" Test scores important in showing no significant difference in attention between study conditions 
The data are presented as the means _+ SD; NS = not significant 
Table 3. Comparison of the behavioral effects of scopolamine + placebo versus scopolamine + TRH 
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Baseline a + 60 min" + 120 min a F P 
Scop+ Plac Scop + TRH Scop+ Plac Scop + TRH Scop +Plac Scop+ TRH 
Restlessness 8.5+ 8.2 8.5± 6.7 16.2±18.9 20.7+_23.3 13.8-t-14.6 J5.6±15A 1.80 <0.12 
Anxious/nervous 12.9-t-14.6 14.0_+12.8 14.3_+14.2 10.7__+ 8.0 9.9+_ 8.7 9.3_+ 7.2 0.03 <0.44 
Alert 58.9-t-20.7 70.8+_18.0 29.0±24.3 37.3_+29.7 31.5+_19.7 40.8_+28.5 2.36 <0.80 
Sad/depressed 4.1-t- 2.1 4.7_ 1.8 4.2_+ 2.7 5.5+__ 3.2 4.7+ 2.4 3.8+ 1.9 0.50 <0.25 
Energetic 38.9_+24.9 40.6+_23.6 8.4_+ 7.9 14.5_+_ 1 4 . 7  13.1_+10.9 14.8__.15.6 0.15 <0.35 
Trouble concentrating 7.6_+ 9.6 7.4_+ 7.5 32.9_+20.3 33.6±22.4 32.1 _+24.2 34.5-+21.7 0.16 <0.35 
Fatigued/tired 17.0+_21.6 17.5_ 1 7 . 6  39.1_+2!.5 29.7±20.8 33.3+_24.0 30.7±19.7 0.98 <0.18 
Drowsy 15.2_+18.6 15.7-+18.7 45.8_+24.3 35.6__.26.7 40.9_+23.4 32.2±24.1 4.31 <0.03 
Disoriented 6.0_+ 2.7 5.0-+ 3.0 16.7_+16.8 19.7±17.7 11.0_+ 9.5 12.2±12.9 0.62 <0.23 
Disjointed speech 6.0_+ 2.7 5.1± 3.2 15.4-+18.9 16.2___17.1 12.4_+11.1 11.0_+12.2 0.00 <0.50 
Euphoric 6.3-t- 3.1 5.2_+ 2.5 6.5_+ 3.7 7.8± 5.9 5.6_+ 2.6 7.5± 7.9 0.06 <0.41 
Contrary/irritable 5.7+_ 2.6 5.2+ 2.5 11.9±15.9 15.7±19.5 8.3_+ 5.4 6.7+_ 3.9 0.16 <0.35 
Drymouth 5.6_+ 3.2 7.5± 5.9 54.6±20.7 46.8+_22.4 42.3_+27.4 48.3±24.6 1.62 <0.21 
Motor retardation 4.4-t- 1.4 4.1_+ 2.0 16.3± 5.4 tl.2_+ 8.5 10.9+_ 6.0 10.3_+ 4.7 0.03 <0.44 
Subjects completed 100 mm (1 =none, 100=severe) visual analog rating scales on the above items. Data are listed for baseline, the 
+ 60, and the + 120 min time points (see Table I) 
a Mean + SD 
processing task significantly declined after scopolamine as 
compared with baseline, with no significant improvement 
after TRH.  
Category retrieval. A decline for baseline scores was signifi- 
cant on both the word and letter portions of  this test follow- 
ing scopolamine. When subjects received scopolamine+ 
TRH,  they had significant attenuation of  this decline in 
their ability to retrieve words for the letter portion of  the 
test only. 
Digit span. On the forward digit span, subjects showed a 
significant decline from baseline after scopolamine, with 
no significant difference on days they received scopola- 
mine+placebo  as compared with scopo lamine+TRH.  A 
statistically significant decline from baseline on the back- 
ward digit span was also evident after scopolamine; this 
decline was significantly attenuated on the days subjects 
received scopolamine + TRH.  
Object recall. Subjects showed a significant decline from 
baseline on object recall after scopolamine, with attenuation 
of  this decline after TRH,  at a trend level of  statistical 
significance. 
Behavioral measures 
The serf-ratings comparing scopolamine + placebo and sco- 
polamine + T R H  showed an increase only in the VAS item 
" d r o w s y "  [F(1,9)=4.31 ; P<0.04]  after scopolamine+pla-  
cebo (Table 3) and in the physical symptom of  "chilled/ 
shivering" (a common, transient side effect of  high-dose 
T R H  (Mellow et al. 1989) [F(1,9) = 7,5; P < 0.01] after sco- 
po l amine+TRH.  No statistically significant correlation 
was found between the " d r o w s y "  and "a le r t "  items and 
scores on the selective reminding task. The additional com- 
parison between drug conditions o f  analog scale measures 
o f  alertness, concentration, and drowsiness using the nmxi- 
mum change from baseline (max delta) did not  differ signifi- 
cantly on the days subjects received scopolamine + placebo 
as compared with the days they received scopolamine + 
TRt t ,  except on the item "restlessness" which was higher 
on the s c o p o l a m i n e + T R H  day ( t=2 .0 ;  P<0.04) .  On the 
physician-rated BPRS and SPMSQ, no significant differ- 
ences were found between subjects on the two drug condi- 
tions. 
Physiological measures 
The A N O V A  comparing blood pressure, heart rate, and 
temperature showed no significant differences between sco- 
polamine +placebo and scopolamine+ T R H  conditions for 
the time points in Table 1. However, the analysis of  the 
retrospectively chosen peak systolic blood pressure (re- 
corded on average 8_+3.7 min after T R H  or placebo ad- 
ministration) did show a significant difference between the 
two drug conditions (t = - 2.3; 10 dr; P < 0.02); after scopo- 
lamine+placebo,  the mean peak systolic blood pressure 
was 117.8 _+ 11.7 mmHg;  and, after scopolamine + TRH,  it 
was 129.5 + 16.6 mmHg. The same was true for mean peak 
diastolic blood pressure (t = - 3.6; 10 df; P < 0.003), with 
the mean peaks at 67.9 -+ 11.9 m m H g  and 87.3 -+ 16.5 mmHg, 
respectively. The mean peak heart rates were not signifi- 
cantly different between drug conditions. 
Discussion 
This study is the first in humans to assess peptidergic neu- 
romodulation of  a drug-induced cognitive effect mediated 
by a classical neurotransmitter system. In addition to scopo- 
lamine's pharmacological specificity, involvement of  the 
cholinergic system in attenuated memory impairment is 
likely because the selective reminding task has been shown 
to be among the most  sensitive of  cognitive tests to the 
effects o f  scopolamine (Caine et al. 1981; Sunderland et 
al. 1987). In our study, this task was also the most  sensitive 
to the effects of  TRH.  The selective reminding task is differ- 
ent from the other tests used because it requires more sus- 
tained concentration and cognitive effort. Thus, our data 
indicate that the cognitive components of  information pro- 
cessing most  sensitive to T R H  are the effort-demanding 
rather than the more automatic or incidental encoding pro- 
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cesses (Hasher and Zacks 1979). Only part  of  the recogni- 
tion memory portion of the vigilance task and part of the 
category retrieval task showed significant differences be- 
tween the scopolamine+placebo and scopolamine+TRH 
conditions (Table 2). The combination of cognitive tests 
used in our paradigm was designed to target specific cogni- 
tive domains as explained in the Methods section. It is diffi- 
cult to evaluate any specific cognitive process (such as ep- 
isodic memory) with any one test. For example, the selective 
reminding task requires among other things, both memory 
and set-shifting capacities. However, attenuation of the sco- 
polamine-induced impairment was also evident on some 
of the other tests of memory, though not as consistently 
as on the selective reminding task, as discussed above and 
shown in Table 2. These results support our contention that 
the drugs were affecting memory. 
T R H  has analeptic effects (Breese et al. 1975; Kativas 
and Horita 1980), which may explain the behavioral rating 
of less drowsiness following TRH, and though it cannot 
be completely determined how much arousal or attentional 
changes may have contributed to the attenuated scopola- 
mine-induced memory impairment after administration of 
TRH;  no change in attention or concentration was found 
on the vigilance-attention and forward digit span tests. In 
addition, no significant difference between drug conditions 
was demonstrated when several analog scale measures of  
attention, concentration, and drowsiness were compared us- 
ing the maximum change from baseline of these items. In 
fact, a significant increase on the item "restlessness" was 
found on the day subjects received TRH. An increase in 
restlessness, if anything, would tend to have a negative ef- 
fect on cognitive testing. Also, the fact that cognitive mea- 
sures of attention were essentially the same between the 
scopolamine + placebo and scopolamine + TRH conditions, 
and that significant correlations were not found between 
cognitive test scores and behavioral measures of alertness 
supports a more specific effect of T R H  on memory and 
learning. Other investigators have found scopolamine (at 
doses comparable to those in our paradigm) to have little 
effect on attention (Safer and Allen 1971 ; Caine et al. 1981), 
although there is some disagreement on this point (Dunne 
and Hartley 1985). Attention is notoriously difficult to mea- 
sure specifically in humans. In addition, a general arousal 
effect was not shown in blood pressure and heart rate by 
the time of cognitive testing, though an increase in blood 
pressure was found shortly after TRH infusion. Statistically 
significant differences were not found in these physiological 
parameters between scopolamine+TRH and scopola- 
mine + placebo after this initial increase on the day subjects 
received TRH. 
Additional data supporting a specific effect of  TRH on 
cognition rather than simply activation are that most at- 
tempts to reverse scopolamine-induced memory impairment 
with stimulant drugs such as amphetamine and methyl- 
phenidate have been unsuccessful (Drachman 1977; Bartus 
1978; Mewaldt and Ghoneim 1979; Yamazaki et al. 1986). 
Further supporting a specific effect of TRH through alter- 
ation of the cholinergic system is the finding that drugs 
like physostigmine and arecoline, which enhance choliner- 
gic transmission, clearly attenuate or reverse the cognitive 
impairment caused by scopolamine in animals and humans 
(Drachman 1977; Bartus 1978; Sitaram et at. 1978). 
While our findings are consistent with results showing 
a modulatory effect of  T R H  on the cholinergic system, 
other studies have shown TRH to increase levels of other 
neuroactive substances such as catecholamines, indolea- 
mines, and vasopressin (Metcalf 1982; Horita et al. J986), 
each of which may have positive memory effects of  their 
own. The absence of a general arousal effect on most behav- 
ioral and physiological measures is evidence against (though 
does not necessarily rule out) a significant involvement of  
catecholamines, as is the absence of a sustained pressor 
response evidence against involvement of vasopressin. The 
involvement of thyroid-stimulating hormone (TSH) or thy- 
roid hormones as mediators of the cognitive effects is un- 
likely for several reasons: TSH crosses the blood-brain bar- 
rier poorly; the high dose of T R H  used in our paradigm 
would not cause supraphysiologic levels of  TSH because 
maximum stimulation of TSH occurs in humans after infu- 
sion of about 500 gg TRH (Snyder and Utiger 1972; Mitsu- 
moto et al. 1986); and thyroid hormones do not begin to 
increase until 90 min after TRH infusion (Jackson 1982). 
Cognitive testing in our paradigm was completed before 
that time point. 
Possible criticisms of the study relate to the blindness 
of the subjects and of the staff regarding whether subjects 
received TRH or placebo. Although our paradigm was set 
up as a double-blind study, high-dose TRH has some specif- 
ic side effects, most notably a shivering response, so subjects 
may have suspected when they received it. Therefore, the 
informed consent signed by subjects was worded so that 
they did not know the hypothesized direction of change 
in cognitive test performance expected after receiving TRH. 
Fortunately, because the side effects of  TRH last for only 
5 10 min, they had subsided by the time of cognitive testing, 
so that the tester remained blind as to whether or not TRH 
was received. 
A significant practice effect contributing to the positive 
cognitive results was ruled out by the randomization of 
the TRH and placebo administration. In fact, eight subjects 
received TRH on the 1st study day, and any overall effect 
of practice (causing improvement on the 2nd study day) 
would have tended to occur and favor test performance 
on the day more subjects received placebo. 
Our results are consistent with findings from animal 
studies showing TRH analogs to attenuate memory and 
learning impairment produced by scopolamine or by lesions 
of the predominantly cholinergic septo-hippocampal path- 
way (Yamazaki et al. 1986; Horita et al. 1987). Moreover, 
brain areas important for memory and learning (the medial 
septum-diagonal band of Broca and the nucleus basalis of  
Meynert) are highly sensitive to one cholinergically me- 
diated central effect of  TRH, the analeptic action (Kalivas 
and Horita 1980; Horita et al. 1986, 1987). 
The proposed mechanism of action of T R H  in our para- 
digm includes presynaptic and/or postsynaptic interactions 
with cholinergic neurons. Presynaptically, TRH has been 
shown to facilitate cholinergic transmission by stimulating 
the turnover rate of acetylcholine (ACh) and attenuating 
the pentobarbital-induced reduction of high-affinity choline 
uptake (Schmidt 1977). Postsynaptically, TRH increases the 
excitatory effects of ACh on cerebral cortical neurons 
(though this action has not been observed by all investiga- 
tors) (Winokur and Beckman 1978), and directly excites 
cholinergic septo-hippocampal neurons (Lamour et al. 
1985). To date, no direct action of TRH at the cholinergic 
receptor has been demonstrated. 
This study demonstrates the ability of T R H  to reverse 
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in part the central anticholinergic effects of scopolamine. 
Although not  all aspects of cognitive function were sensitive 
to TRH,  the demonstrated positive effects engender specu- 
lation about  other possible neuropeptide modulators and 
their investigation using similar pharmacologic models of 
cognitive impairment.  Investigations into the therapeutic 
potential of the cholinergic enhancing properties of high- 
dose T R H  are ongoing. In a recent study from our group, 
patients with Alzheimer's disease showed a modest im- 
provement in memory after acute infusion of high-dose 
T R H  as compared with placebo (Mellow et al. 1989). Fur-  
ther studies using TRH as a neuropharmacological probe 
are necessary to delineate its psychobiological effects and 
to study the mechanism of peptidergic neuromodulat ion.  
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